Girard Partners’s Moderna MRNA Stock Holding History

Girard Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-755	Closed	-$290K	–	262
2021 Q3	$290K	Buy	+755	New	+$278K	0.04%	196

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Girard Partners's MRNA Position: Q4 2021 in Review

Girard Partners sold out of Moderna (MRNA) in Q4 2021, closing a stake of 755 shares — an estimated $290K sold.

Girard Partners first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $290K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Girard Partners reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Girard Partners sold 755 Moderna shares in Q4 2021, an estimated $290K.
Girard Partners first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Girard Partners's Moderna position peaked at $290K in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Girard Partners's 13F filing for Q4 2021, filed 2 Feb 2022.